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Mucosal Biomarkers of Colorectal Cancer Risk Do Not
Increase at 6 Months Following Sleeve Gastrectomy, Unlike
Gastric Bypass
Prashant Kant1, Sarah L. Perry1, Simon P. Dexter2, Amanda D. Race3, Paul M. Loadman3 and Mark A. Hull1
Objective: The hypothesis that sleeve gastrectomy (SG) is not associated with an increase in mucosal
colorectal cancer (CRC) biomarkers, unlike Roux-en-Y gastric bypass (RYGB), was tested.
Design and Methods: Rectal mucosa, blood, and urine were obtained from morbidly obese patients (n
5 23) before and after (median 28 months) SG, as well as from nonobese controls (n 5 20). Rectal epi-
thelial cell mitosis and apoptosis, crypt size=fission, and pro-inflammatory gene expression were meas-
ured, as well as systemic inflammatory biomarkers, including C-reactive protein (CRP).
Results: The mean pre-operative body mass index in SG patients was 65.7 kg=m2 (24.7 kg=m2 in con-
trols). Mean excess weight loss post-SG was 38.2%. There was a significant increase in mitosis fre-
quency, crypt size, and crypt fission (all P < 0.01) in SG patients versus controls, as well as evidence of
a chronic inflammatory state (raised CRP and mononuclear cell p65 NFjB binding), but there was no sig-
nificant change in these biomarkers after SG, except CRP reduction. Macrophage migration inhibitory
factor mRNA levels were increased by 39% post-SG (P 5 0.038).
Conclusions: Mucosal biomarkers of CRC risk do not increase at 6 months following SG, unlike RYGB.
Biomarkers of rectal crypt proliferation and systemic inflammation are increased in morbidly obese
patients compared with controls.
Obesity (2014) 22, 202–210. doi:10.1002/oby.20493
Introduction
The number of bariatric surgical procedures that are performed con-
tinues to increase in line with the increasing global prevalence of
obesity (1,2). Several bariatric surgical techniques are performed
routinely including purely “restrictive” procedures such as gastric
banding, as well as procedures that are believed to induce weight
loss via a combination of restrictive and malabsorbtive mechanisms
such as Roux-en-Y gastric bypass (RYGB) (1). Sleeve gastrectomy
(SG) is now performed more widely, either alone or as part of a
two-stage procedure followed by a duodenal switch (3).
A link between obesity and increased colorectal cancer (CRC) risk is
firmly established (4). However, the effect of bariatric surgery on
future CRC risk remains unclear. Initial reports suggested that bariat-
ric surgery was associated with a reduction in overall cancer risk and
risk associated with some obesity-related cancers including
postmenopausal breast cancer (5-7). However, these studies were too
small to determine specific effects on CRC risk. In a large popula-
tion-based study in Sweden, we recently reported that the standar-
dized incidence ratio (SIR) for CRC risk actually increased with time
after bariatric surgery such that the SIR was 2 (95%CI 1.5-2.6) 10
years after surgery compared with a SIR of 1.25 for a group of obese
patients who did not undergo bariatric surgery, which remained stable
over time (8). The increased CRC SIR was shared by those who
underwent restrictive procedures (limited to gastric banding and verti-
cal-band gastroplasty), as well as the more common RYGB (8). These
observational findings concurred with our previous colorectal mucosal
biomarker studies, in which a mucosal hyper-proliferative state
(increased epithelial cell mitosis frequency and crypt size) persisted at
least three years after RYGB compared with pre-operative morbidly
obese patients and normal weight controls (9,10).
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Possible mechanistic explanations for increased CRC risk after bari-
atric surgery include increased colorectal mucosal exposure to bile
acids (11,12)and=or a carcinogenic metabolomic profile of intestinal
luminal content secondary to postoperative changes in diet and=or
gut microflora (13,14).
As the “restrictive” procedure SG is increasingly performed at the
expense of RYGB and results in similar degrees of weight loss (3),
we tested the hypothesis that SG would not be associated with an
increase in the colorectal mucosal biomarkers that we had observed
in our previous studies of colorectal mucosal changes after
“malabsorbtive” RYGB.
Obesity is recognized as a state of chronic, low-grade, systemic
inflammation (4). One hypothesis is that there is subclinical colorectal
mucosal inflammation in obesity that could drive colorectal carcino-
genesis. Therefore, we measured levels of mucosal pro-inflammatory
gene expression, and changes following SG, in obese patients and
nonobese controls, in comparison with levels of systemic inflamma-
tory biomarkers such as C-reactive protein (CRP).
Methods
All aspects of the study were approved by the Leeds (East) Research
Ethics Committee (07=Q1206=29 and 08=H1311=42). Written, informed
consent was obtained from all participants.
Study subjects and study pathway
Consecutive patients scheduled for SG at St James’s University Hos-
pital and The Nuffield Hospital, Leeds were contacted 2 weeks prior
to surgery. Patients were eligible if aged between 18 and 65 years
with a body mass index (BMI) 35 kg=m2 and if able to provide
informed consent. The control group consisted of patients aged
18-65 years with a BMI 18.5-29.9 kg=m2, who were undergoing
anal canal surgery, for which bowel preparation was not required.
Patients were excluded if there was a history of significant gastroin-
testinal disease (including CRC, colorectal adenoma, inflammatory
bowel disease, or coeliac disease), previous colorectal surgery,
bleeding diathesis, current anticoagulation therapy or regular use of
aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs;
defined as 4 doses per week for more than three months).
A full medical and drug history was taken prior to SG as described
(9). Height, weight, and BMI were measured. Venous blood was
obtained and urine was collected the day before surgery. Six rectal
mucosal biopsies were obtained by rigid sigmoidoscopy under general
anaesthetic immediately prior to surgery. Biopsies were taken from 8-
10 cm above the dentate line on the posterior wall of the unprepared
rectum using 2.2-mm jaw, single-use biopsy forceps (Boston Scien-
tific, MA). Any patient with macroscopic evidence of mucosal inflam-
mation or polyps was excluded. SG patients underwent repeat assess-
ment and sampling in clinic approximately 6 months after SG.
Blood, urine and mucosal biopsy handling
Serum and plasma were obtained using SST II advanceTM and
EDTA tubes (both BD VacutainerVR ), respectively, and stored at
280C. Peripheral blood mononuclear cells (PBMCs) were isolated
in sodium citrate tubes (BD VacutainerVR CPTTM), which were cen-
trifuged at 1500 g for 20 mins at 20C within 2 h of venepuncture.
Twenty milliliter of urine was collected in a sterile container and stored
at280C. All urine samples were frozen within 2 h of collection.
Two rectal biopsies were placed into Carnoy’s fixative for 2 h at
20C and then transferred to 70% (v=v) ethanol for storage at 4C
(9). Two biopsies were fixed in 10% formalin for 24 h and then em-
bedded in paraffin. One biopsy was placed in 500 lL Tris-buffered
saline (TBS), pH 7.4 for measurement of ex vivo PGE2 synthesis as
described (9). One biopsy was placed in 1 ml of TRIzolVR (Invitro-
gen, Paisley) and stored at 280C.
Laboratory analyses
Cytokine and CRP measurement. Levels of serum TNFa and
IL-6 were measured using QuantkineVR Immunoassays (R&D Systems,
Minneapolis). Serum CRP levels were analyzed using a high-sensitiv-
ity immunoassay (Advia 1650=2400, Siemens HealthCare Diagnos-
tics, Newbury, UK). The lower limit of detection was 0.2 mg=L.
Whole crypt microdissection and mitosis counting. The num-
ber and position of mitotic epithelial cells in microdissected rectal
crypts was determined by one observer (PK) as described in Ref.
(9). Inter-observer agreement between this study and the previous
RYGB study (9) has previously been confirmed (10).
Immunohistochemistry. Immunohistochemistry for neo-cytokera-
tin (CK) 18 was performed as described in Ref. (9).
PBMC culture and NFjB DNA binding assay. PBMCs were
washed twice in Dulbecco’s phosphate-buffered saline (PBS; Invitro-
gen). Cells were then counted with a haemocytometer. PBMCs were
re-suspended in RPMI 1640 with GlutaMAXTM supplemented with
100 U=ml penicillin, 100 mg=ml streptomycin and 10% (v=v) fetal
calf serum (Harlan Seralabs, UK) and cultured at 37C in the pres-
ence of 5% CO2 for 2 h in the presence or absence of 1 mg=ml
Escherichia coli serotype 026:B6 lipopolysaccharide (LPS; Sigma).
Nuclear protein was isolated using a nuclear protein extraction kit
(Active Motif, CA, USA). The protein concentration was measured
using a colorimetric DCTM Protein Assay kit (Bio-Rad, CA, USA).
NFjB binding activity was measured using the TransAM NFjB
Family Transcription Factor Assay KitTM for p50 (NFjB1), P52
(NFjB2), p65 (Rel A), Rel B and c-Rel subunits (Active Motif) on
5 lg total protein samples. Data are presented as the binding activ-
ity, measured as the absorbance at 450 nm using an Opsys MR spec-
trophotometer (Dynex Technologies, Worthing, UK) relative to the
same amount of control human B cell lymphoblast nuclear extract.
Preliminary experiments demonstrated that there was significant
degradation of NFjB binding in nuclear extracts stored at 280C
when measured 9 months apart (data not shown). Therefore, all
NFjB DNA binding assays were performed strictly 9 months after
nuclear protein extraction.
Real-time -PCR. Total RNA was isolated and cDNA synthesized
as described in Ref. 9. SYBR GreenTM real-time PCR (Applied Bio-
systems, Warrington, UK) was carried out using an ABI PRISMVR
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7900HT Sequence Detection System (Applied Biosystems) as
described in Ref. 9. Primers used are detailed in Supporting Infor-
mation Table 1. Each reaction cycle consisted of heating to 90C
for 2 min, followed by 10 min at 50C. This was followed by 40
amplification cycles of heating to 95C for 15 seconds followed by
cooling at 60C for 1 min. Each sample was performed in duplicate
and the absence of cDNA served as a “no template” negative con-
trol. Individual pro-inflammatory gene transcript levels were quanti-
fied by the DCt method using glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) as the reference gene transcript (9).
Urinary PGE-M assay by liquid chromatography-tandem ma-
ss spectrometry. Liquid chromatography-tandem mass spectrom-
etry (LC-MS=MS) was performed on an Acquity Ultra Performance
LCTM (UPLCTM) System linked with a Quattro PremierTM XE
(Waters Corp, Milford, USA) bench-top tandem quadrupole mass
spectrometer operated in multiple reaction monitoring (MRM) mode.
Samples were prepared and extracted using solid phase extraction as
described in Ref. 15. Separation was achieved using an Acquity
UPLC BEH C8 Column, 2.1 3 100 mm, 1.7 mm (Waters, Milford,
USA) and a mobile phase A of 95:5, 0.1% (v=v) acetic acid:acetoni-
trile, and mobile phase B of 50:50, 0.1% (v=v) acetic acid:acetoni-
trile. Samples were separated by a gradient of 98-40% mobile phase
A over 15 min at 300 ll=min. The mass spectrometer was operated
in negative ion mode as described in Ref. 15, with the exception that
the cone voltage was set at 19 V. MRM channels were established
for PGE-M (m=z 385.2 > 336.2) and the internal standard PGE-Md6
(m=z 391.2 > 339.2) (both Cayman Chemical, Ann Arbor, MI). PGE-
M was quantified against the internal standard with calibration using
10-100 ng=ml authentic PGE-M. The limit of detection was 1 ng=ml.
The urinary creatinine (Cr) concentration in mg=ml was measured
using an ADVIA 1800 analyzer (Siemens). The urinary PGE-M con-
centration is presented as ng PGE-M=mg Cr.
The PGE2 level in rectal biopsy-conditioned TBS was measured by
immunoassay (Cayman Chemical) as described in Ref. 9.
Statistical analysis. Data were analyzed for normality using the
Shapiro-Wilk test. Normally distributed and log transformed data
were compared using Student’s t-test and presented as the mean and
95% confidence interval (CI). Unpaired categorical data were compared
using the v2 or Fisher’s exact test. Categorical data were compared
using the Mann-Whitney U test and presented as the median value and
inter-quartile range (IQR). For paired data, the Student’s paired t-test or
Wilcoxon signed rank test was used. Paired categorical data were com-
pared using the McNemar test. Pearson’s coefficient was used to test
for correlations between normally distributed variables, whilst Spear-
man’s coefficient was used for non-normally distributed data.
Results
Clinical characteristics of the
non-obese=morbidly obese cohorts and
outcomes after SG
Between October 2008 and July 2010, 23 out of 35 potential SG
patients consented to participate in the study and provide blood,
urine, and rectal mucosal samples. Seven patients declined to partic-
ipate and five eventually underwent RYGB.
Postoperative samples were obtained a median 28 weeks (IQR 27-31
weeks) after SG from 21 patients. Two patients withdrew consent.
In one case, postoperative rectal mucosal samples were not obtained
as anticoagulant therapy had been started after surgery. Urine sam-
ples were not obtained in two patients before SG and in another
patient after SG, giving 18 paired urine samples.
Pre- and postoperative BMI values are displayed in Supporting In-
formation Figure 1. The mean individual weight loss was 44.9
(standard error of the mean [SEM] 3.6) kg, equating to a mean indi-
vidual excess weight loss (EWL) of 38.3 (SEM 3.8) %.
Twenty nonobese patients scheduled for either haemorrhoidectomy
(n 5 19) or anal sphincter collagen injection (n 5 1) consented to
provide blood, urine, and rectal mucosal samples at the time of sur-
gery. Urine samples were not obtained in eight cases.
The two groups were well matched for age and sex (Table 1. How-
ever, there were significantly more subjects who used a NSAID and
former smokers in the morbidly obese group, as well as an expected
nonsignificant excess of individuals with diabetes.
Morbid obesity is associated with a rectal
mucosal hyper-proliferative state that does not
alter 6 months after SG
Consistent with our previous studies of RYGB patients (9,10), mor-
bidly obese patients had a significantly higher crypt mitosis fre-
quency (P < 0.01) and significantly larger crypts compared with
nonobese controls ( P < 0.01; Figure 1A,B and Table 2. Morbidly
obese subjects had a significantly greater percentage of mitotic epi-
thelial cells in crypt zones 4 and 5, indicating an expanded prolifera-
tive compartment (Figure 1C and Table 2. Morbidly obese patients
also exhibited more crypts in fission than nonobese controls ( P <
0.01; Figure 1D and Table 2.
TABLE 1 Clinical characteristics of nonobese control and
morbidly obese (presleeve gastrectomy) patients
Control
Morbidly
obese P valuea
n 20 23
Mean BMI (SEM) 24.7 (0.6) 65.7 (2.4) < 0.001
Mean age (range) 45 (22-63) 46 (30-63) 0.75
Sex (male:female) 8:12 8:15 0.76
Smoking status (%)b
Never smoked
Former smoker
Current smoker
12 (60)
3 (15)
5 (25)
7 (30)
10 (44)
6 (26)
0.052
0.054
0.99
Diabetes mellitus (%) 2 (10) 7 (33) 0.13
NSAID usec (%) 2 (10) 9 (40) 0.03
aNormally distributed data (BMI and age) were compared using the unpaired t-test.
Differences in sex were compared by the v2 test. Differences in all other categorical
data between the two groups were compared by Fisher’s exact test.
bNever smoked defined as a lifetime smoking consumption <100 cigarettes; for-
mer-smoker defined as a lifetime smoking consumption >100 cigarettes ceasing
>1 year previously; current smoker defined as either presently smoking or ceasing
<1 year ago.
cThe use of any dose of NSAID (aspirin or nonaspirin NSAID) during the preceding
28 days.
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Neo-CK18-positive apoptotic epithelial cells in rectal biopsies were
sparse as described previously (9). There were no significant differ-
ences between the apoptosis index or the percentage of patients
numbers with at least one neo-CK18-positive cell-containing crypt
between morbidly obese subjects and nonobese controls (P 5 0.85;
Table 2.
By contrast with the effect of RYGB on rectal epithelial cell kinetics
(9), there was no significant change in the crypt mitosis frequency
(P 5 0.46), crypt size (P 5 0.98), or the percentage of mitotic cells
in zones 4 and 5 at 6 months after SG compared to pre-operative
values (P 5 0.92; all Wilcoxon signed rank test; Figure 1A-C and
Table 2. There was also no significant difference in the number of
FIGURE 1 Rectal mucosal crypt biomarker values in patients before and after SG compared with nonobese controls. (A) Mitosis
frequency (mean number of mitotic cells per crypt). Open circles represent data from nonobese patients (n 5 20). Filled circles
joined by a line represent data from morbidly obese patients before (Pre) and after (Post) SG (n 5 20 pairs). Values below the
graph represent the median value for each group. * P 5 0.006; Mann-Whitney test. (B) Mean rectal crypt area. Open circles rep-
resent data from nonobese patients (n 5 20). Filled circles joined by a line represent data from morbidly obese patients before
(Pre) and after (Post) SG (n 5 20 pairs). Horizontal and vertical bars represent the median and IQR values for each dataset
respectively. Values below the graph represent the median value for each group. *P 5 0.002; Mann-Whitney U test. (C) Mitosis
crypt distribution in crypt zones 1-5 in nonobese controls and patients before (Pre) and after (Post) SG. The numbers in each bar
are mean percentage values for each zone. Because of the small numbers in zones 4 and 5, these values were combined. *P 5
0.003; Mann-Whitney U test. (D) The number of crypts in fission. Open circles represent data from nonobese patients (n 5 20).
Filled circles joined by a line represent data from morbidly obese patients before (Pre) and after (Post) SG (n 5 20 pairs). Adjacent
bars demonstrate the median value for each dataset. The number of patients exhibiting no crypt fission (xN) is displayed next to
the zero values for each dataset. Numbers below the graph represent the percentage of individuals exhibiting equal to or more
than one crypt in fission. The percentage of patients exhibiting crypt fission was significantly higher in morbidly obese patients
prior to SG compared with nonobese patients. *P 5 0.002; v2 test.
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crypts in fission or the proportion of patients exhibiting crypts in fis-
sion 6 months after SG compared with baseline values (P 5 0.18;
McNemar test; Figure 1D and Table 2.
Changes in systemic inflammation
biomarkers following SG
As predicted by existing data (9,10), morbidly obese patients prior
to SG had significantly higher levels of serum CRP, IL-6, and TNFa
than nonobese patients (P < 0.001; Mann-Whitney U test; Figure 2
and Table 2.
Weight loss following SG was associated with a significant reduc-
tion in serum CRP (P < 0.01; Wilcoxon signed rank test; Figure 2
and Table 2, the magnitude of which correlated with the degree of
postoperative weight loss at 6 months (Supporting Information
Figure 2). However, there were no significant changes in serum IL-6
TABLE 2 Summary of biomarker comparisons between nonobese controls and patients before (pre) and after (post) sleeve
gastrectomy
Nonobese
SG
Pre Post
Weight (kg)a 72.1 6 2.3 188.7 6 9.0 143.8 6 7.7
BMI (kg=m2 )a 24.7 6 0.6 65.7 6 2.4 50.1 6 2.0
% Excess weight lossa - - 38.3 6 3.8
Rectal crypt measurements
Mitosis frequency (per crypt) 3.6 (2.3-4.3) 4.4b (3.7-5.5) 4.5 (3.7-6.8)
Crypt area (mm2) 0.032 (0.029-0.035) 0.039b (0.036-0.045) 0.038 (0.036-0.045)
Crypt branching
Number of branching crypts=patient 0.5 (0-3) 1.0b (0-3.5) 0.5 (0-6)
% patients with  1 branching crypt 45 90b 65
Apoptosis
M30 positive crypts=patient 0.68 (0.24-1.0) 0.54 (0.31-0.81) 0.17 (0.17-0.17)
% patients with M30-positive crypts 33.3 25 5
Mucosal mRNA Fold difference from nonobesec Fold increase from pre-SG leveld
MIF - 1.24 (0.98-1.56) 1.39 (1.04-1.87)b
COX-1 - 1.10 (0.96-1.26) 0.57 (0.26-1.13)
COX-2 - 0.31 (0.26-0.38) 1.79 (0.93-3.49)
TNFa - 0.83 (0.77-0.89) 1.03 (0.41-2.62)
IL-6 - 0.90 (0.72-1.12) 1.40 (0.62-3.20)
IL-1b - 0.68 (0.58-0.79) 0.98 (0.51-1.89)
Urinary PGE-M 11.8 (9.6-29.2) 16.3 (12.1-24.2) 10.9 (8.4-23.4)
Systemic inflammatory markers
CRP (mg=l) 0.5 (0.2-2.0) 17.5 (10.5-25.3)b 13.5 (3.4-16.3)e
TNFa (pg=ml) 1.07 (0.82-1.21) 1.99 (1.42-2.44) 1.55 (1.35-2.21)
IL-6 (pg=ml) 0.72 (0.24-1.78) 5.01 (2.18-8.31) 5.35 (3.27-6.95)
PBMC NFjB binding activity
p50a
Unstimulated 0.33 6 0.03 0.37 6 0.02 0.41 6 0.03
LPS stimulated 0.50 6 0.03 0.55 6 0.02 0.57 6 0.03
p65a
Unstimulated 0.42 6 0.04 0.62 6 0.04b 0.64 6 0.04
LPS stimulated 0.62 6 0.08 0.99 6 0.08b 1.06 6 0.05
aValues indicate the mean 6 SEM. All other values are stated as the median (IQR).
bIndicates statistically significant difference compared with nonobese group; P  0.05.
cFold difference between the nonobese and pre-SG group is relative to GAPDH expression.
dFold increase and 95% confidence interval are converted from the mean DDCt values
eIndicates a statistically significant difference compared with pre-SG values; P  0.05
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or TNFa levels (P 5 0.83 and 0.89, respectively; Wilcoxon signed
rank test) 6 months after SG (Figure 2 and Table 2).
We also examined NFjB DNA binding in PBMCs as a biomarker
of innate immune activation in obesity (16). We first confirmed that
p65 (Rel-A) and p50 are the NFjB subunits that exhibit the highest
level DNA binding in obese human PBMCs (Supporting Information
Figure 3). We then restricted our analysis to p65 and p50 DNA
binding in nuclear extracts from PBMCs isolated from nonobese
controls and morbidly obese patients, before and after SG. Activa-
tion with LPS acted as a positive control for NFjB binding with a
consistent increase in NFjB binding observed upon LPS stimulation
in all three groups (Figure 3A). Binding of p65 was increased in
both un-stimulated and LPS-stimulated PBMCs from morbidly obese
patients compared with nonobese individuals (Figure 3B,C and
Table 2). However, in keeping with the absence of change in serum
TNFa levels after SG, there was no significant difference between
NFjB binding in PBMCs before and after SG, cultured in either the
presence or absence of LPS (Figure 3B,C and Table 2). Interest-
ingly, there was no difference in DNA binding of the p50 subunit in
PBMCs between morbidly obese patients and nonobese controls
despite the fact that LPS stimulation induced significant p50 binding
in all three groups (Table 2).
Mucosal and systemic PGE2 synthesis in
morbidly obese patients
There was no significant difference in ex vivo mucosal PGE2 synthesis
between morbidly obese patients and nonobese controls (data not shown).
We also measured urinary 11a-hydroxy-9, 15-dioxo-2, 3, 4, 5-tetra-
nor-prostane-1, 20-dioic acid (PGE-M) levels as a marker of
FIGURE 2 Serum levels of CRP, IL-6 and TNFa in patients before and after SG compared with nonobese con-
trols. Open circles represent (A) CRP, (B) IL-6, and (C) TNFa data from nonobese patients (n 5 20; multiple
data points overlap). Filled circles joined by a line represent data from morbidly obese patients before (Pre)
and after (Post) SG (n 5 21 pairs). Values below the graph represent median serum concentration values.
**P < 0.001; Mann-Whitney U test. *P < 0.01; Wilcoxon signed rank test.
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systemic PGE2 production (15). The coefficient of variation for 10
and 100 ng=ml authentic PGE-M was 11.3% and 9.6%, respectively,
(n 5 9 for both). Although median levels of urinary PGE-M were
lower in the nonobese group compared with the morbidly obese
group prior to SG, this difference did not reach statistical signifi-
cance (Figure 3D; P 5 0.32; Mann-Whitney U test). There was also
no difference in urinary PGE-M levels or in morbidly obese patients
before and after SG (P 5 0.25; Wilcoxon signed rank test).
Changes in rectal mucosal pro-inflammatory
gene expression after SG
There was no significant difference in the mean GAPDH Ct values
between nonobese individuals and morbidly obese patients prior to
SG (Supporting Information Figure 4).
DCt values for individual pro-inflammatory gene transcripts varied
widely (Figure 4A), but were normally distributed and so were
FIGURE 3 NFjB p65 DNA binding in PBMCs from patients before and after SG compared with nonobese
controls. (A) p65 DNA binding in PBMCs from nonobese controls and patients before (Pre) and after (Post)
SG. Open bars represent the mean relative DNA binding in un-stimulated PBMCs, black bars represent
mean relative DNA binding in LPS-stimulated PBMCs. Error bars represent the SEM. *P < 0.01 for the differ-
ence between the nonobese values and morbidly obese group data before SG. (B) Individual patient PBMC
p65 DNA binding data. Open circles represent DNA binding in un-stimulated PBMCs from nonobese
patients. Filled circles joined by a line represent data from morbidly obese patients before (pre) and after
(post) SG. Adjacent bars represent the mean and 95% CI. *P < 0.01 for the difference between the non-
obese values and morbidly obese group data before SG. (C) Corresponding p65 DNA binding values from
LPS-stimulated PBMCs. *P < 0.01 for the difference between the nonobese values and morbidly obese
group data before SG. *P < 0.01 for the difference between the nonobese values and morbidly obese group
data before SG. (D) Urinary PGE-M levels in nonobese controls and morbidly obese patients before and after
SG. Open circles represent data from nonobese patients (n 5 12). Filled circles joined by a line represent
paired data from morbidly obese patients before (Pre) and after (Post) SG (n 5 18). Values below the graph
represent the median urinary PGE-M level for each group.
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compared using parametric tests. There were consistently high levels
of migration inhibitory factor (MIF) mRNA in rectal mucosal biop-
sies compared with transcript levels for the other genes examined,
expression of which was more variable than MIF (Figure 4A). There
was no significant difference in mRNA levels of any pro-inflamma-
tory gene between nonobese patients and morbidly obese patients
prior to SG surgery (Figure 4A and Table 2).
Paired analysis of GAPDH Ct values before and after SG demon-
strated that surgery also had no significant effect on reference GAPDH
mRNA levels (P 5 0.13; Mann-Whitney U test; Supporting Informa-
tion Figure 4). Moreover, DCt values before and after SG were nor-
mally distributed. There was a small, but significant, 39% increase in
MIF mRNA level following SG (mean fold change [calculated as the
2DDCt value] 1.39; P 5 0.038, paired t-test). However, there were no
significant changes in the expression of TNFa, IL-1b, IL-6, COX-1, or
COX-2 over the same time period (Figure 4B and Table 2).
Discussion
Rectal mucosal crypt biomarkers of CRC risk did not increase 6
months after SG, unlike RYGB (9,10), in our small study. In the
light of our recent observation that CRC risk may increase with
time after RYGB, gastric banding, and vertical-band gastroplasty
(8), it will be important to determine long-term colorectal neoplastic
risk in the increasing number of individuals who now undergo SG,
as well as repeat biomarker studies in a larger cohort study. Our pre-
diction, based on these biomarker studies, would be that SG may
not be associated with elevated future CRC risk compared with indi-
viduals with excess body weight-related elevated CRC risk, who do
not undergo bariatric surgery. However, in the continuing absence
of a prospective validation of rectal mucosal parameters as CRC
risk biomarkers, a long-term cohort study of SG patients using CRC
outcomes is essential. A direct biomarker or CRC risk comparison
between SG and other restrictive procedures has yet to be carried
out in order to explore potential discrepancies in colorectal out-
comes between the different “restrictive” surgical approaches. One
possible explanation for differences between outcomes after various
“restrictive” procedures is that SG involves gastric resection, which
affects hormonal (ghrelin) and adiopkine (adiponectin) profiles dif-
ferently from gastric banding (16,17).
It should be noted that, although the %EWL after SG was similar to
that observed in our previous RYGB study (9), the absolute BMI of
patients undergoing SG was significantly higher than the RYGB
study (9). This makes direct comparison between the two datasets
more difficult but it is unlikely to confound the lack of an increase
in mucosal biomarkers in the SG patients as the higher absolute
postoperative body weight in SG patients might be expected to be
associated with elevated biomarker values compared with RYGB
patients. Similar differences in clinical factors such as diabetes and
NSAID use between the obese patients and nonobese controls were
observed in our previous RYGB study (9). Therefore, we do not
believe that these clinical factors are likely to have confounded the
biomarker data herein.
Importantly, our nonobese controls did not receive any bowel prepa-
ration, unlike previous studies (9). We have confirmed our earlier
data (9) that rectal crypt biomarkers are elevated in morbidly obese
individuals compared with nonobese controls. The lack of bowel
preparation allowed a definitive comparison of mucosal pro-inflam-
matory gene expression in morbidly obese individuals and nonobese
controls avoiding potential effects of bowel preparation on mucosal
gene expression. The lack of any difference in mucosal transcript
levels between morbidly obese patients and nonobese controls
argues against the presence of local, mucosal inflammation associ-
ated with elevated systemic inflammatory biomarkers in obesity (4).
However, it should be noted that the study was small predisposing
to possible type II statistical error and that the control group
FIGURE 4 Relative expression of rectal mucosal pro-inflammatory genes in non-
obese individuals and morbidly obese patients before and after SG as measured
by RT-PCR. (A) The distribution of DCt values (normalised to GAPDH) for nonobese
controls (open circles) and morbidly obese individuals before SG (closed circles).
Note the inverted y-axis with lower DCt values indicating a higher level of gene
expression (relative to GAPDH) than higher DCt values. Adjacent bars represent the
median DCt value for each group of DCt values. (B) Changes in rectal mucosal
transcript expression following SG. Each data point represents the DDCt value of
an individual patient for a particular gene (DCtPre-SG minus DCtPost-SG) normalised to
GAPDH expression. Positive DDCt values represent an increase in transcript
expression following SG and negative values represent a reduction. Adjacent bars
represent the mean DDCt value; error bars denote the 95% confidence interval.
*There was a statistically significant increase observed in MIF mRNA levels following
SG (P 5 0.038; paired t-test).
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contained 9 (45%) overweight individuals (BMI 25.0-29.9 kg=m2),
which could have masked any relationship between BMI and muco-
sal gene expression in our study.
The increase in MIF transcript levels that was observed in rectal mu-
cosa after SG is consistent with the small degree of MIF induction
observed at a similar time-point after RYGB (10). In RYGB patients,
MIF mRNA levels then increased dramatically at three years after
surgery (10). It will be important to determine whether a similar phe-
nomenon occurs during longer term follow-up of SG patients.
This is the first study to investigate differences in PBMC NF NFjB
DNA binding between morbidly obese patients and nonobese
controls, as well as in morbidly obese patients following SG, as a sur-
rogate biomarker of systemic inflammation and=or “classical” M1 tis-
sue macrophage activation. Although PBMC NFjB “activity”, as
measured by Rel-A DNA binding, was higher in morbidly obese
patients compared with nonobese controls, in keeping with the previ-
ous observations (18), there was no decrease following significant sur-
gical weight loss. This is consistent with the lack of change in serum
TNFa levels, but is not consistent with the observations that PBMC
NFjB binding is reduced following modest calorie-restriction- and
exercise-induced weight loss (19). In addition, Goyenechea and col-
leagues have also reported that Rel-A mRNA levels are reduced in
obese individuals who maintain low calorie diet-induced weight loss
(20). It is possible that, despite significant post-SG EWL, the PBMC
NFjB “activity” level may reflect residual, postoperative excess body
weight. It should also be noted that our protocol included ex vivo
PBMC culture in order to provide an internal positive control for
PBMC activation, unlike previous studies (18-20).
The level of PGE-M, the stable tetranor metabolite of PGE2, in
urine is established as the best indicator of systemic PGE2 synthesis
(21,22). However, there has been no previous study of the relation-
ship between body weight and urinary PGE-M level (22). We did
not find any evidence for elevated PGE2 synthesis in morbidly obese
subjects, nor any change in urinary PGE-M levels after SG.
In summary, we have confirmed that rectal mucosal biomarkers of
future CRC risk are increased in morbidly obese patients compared
with nonobese controls. However, SG is not associated with a fur-
ther increase in these biomarkers, unlike the other common bariatric
procedure RYGB (9,10). Future CRC risk after SG requires careful
evaluation and comparison with alternative bariatric procedures.O
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